FDA announced a series of guidance documents on the development of generic transdermal and topical delivery systems (TDS). These include: ● guidance on evaluating adhesive performance ● guidance on evaluating the in vivo skin irritation and sensitization potential, and ● 25 product-specific guidances for applicants seeking to develop generic copies.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
